PRTC News and Press, PureTech Health plc From 04/25/24

Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs, 1 launch of two new Founded Entities, 2 including a $100 million Series A financing for Seaport, and the $14 billion acquisition of Karuna by Bristol Myers Squibb Robust bala...

2024-04-17 05:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Topline results are expected in Q4 2024 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in ...

LYT-200 is being evaluated in locally advanced/metastatic solid tumors, including head and neck cancers, as well as in hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndrome Phase 1b and Phase 1/2 clinical trials of LYT-200 ongoing Pu...

Bharatt Chowrira, Ph.D. , J.D., named Chief Executive Officer of PureTech; PureTech Co-founder, Eric Elenko, Ph.D., promoted to President PureTech Founding Chief Executive Officer, Daphne Zohar, to lead Seaport as Chief Executive Officer, together with former Karuna Chief Executiv...

2024-03-23 07:52:56 ET Summary PureTech Health's founded entity, Karuna Therapeutics, has been successful in developing a therapeutic with an optimized profile. Karuna Therapeutics was acquired by BMY for $14 billion. PureTech's lead asset, LYT-100, may be a promising treatmen...

2024-03-19 10:31:09 ET More on PureTech Seeking Alpha’s Quant Rating on PureTech Historical earnings data for PureTech Financial information for PureTech Read the full article on Seeking Alpha For further details see: PureTech announces $10...

Proposed capital return of $100 million by way of a Tender Offer at 250 pence per Ordinary Share Premium of 25% to PureTech’s trailing three-day VWAP Proposed Tender Offer follows completion of Karuna Therapeutics' $14 billion acquisition by Bristol Myers Squibb. The Tender...

2024-03-18 19:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Acquisition centered on KarXT, which was invented at PureTech, as a potential first-in-class treatment for schizophrenia in adults PureTech to receive approximately $293 million gross proceeds from Karuna equity position in addition to being eligible for further milestones and royalty pay...